RT Book, Section
A1 Ezzedine, Khaled
A1 Harris, John E.
A2 Kang, Sewon
A2 Amagai, Masayuki
A2 Bruckner, Anna L.
A2 Enk, Alexander H.
A2 Margolis, David J.
A2 McMichael, Amy J.
A2 Orringer, Jeffrey S.
SR Print(0)
ID 1161324334
T1 Vitiligo
T2 Fitzpatrick's Dermatology, 9e
YR 2019
FD 2019
PB McGraw-Hill Education
PP New York, NY
SN 9780071837798
LK dermatology.mhmedical.com/content.aspx?aid=1161324334
RD 2024/09/16
AB AT-A-GLANCEVitiligo  is  a  common  autoimmune  disease  of  the  skin  that  causes  depigmentation  through  T-cell–mediated  destruction  of  melanocytes.Pathogenesis  is  multifactorial,  including  genetic  predisposition,  autoimmunity,  and  environmental  factors.Vitiligo  can  cause  significant  social  stigma,  with  serious  implications  for  mental  health.Correlates  with  increased  risk  of  other  autoimmune  diseases,  but  decreased  risk  of  skin  cancer.Clinical  signs  of  lesional  activity  include  confetti,  trichrome,  and  inflammatory  lesions,  as  well  as  koebnerization.Reversible  with  treatment,  but  only  in  areas  with  normally  pigmented  hair.Effective  treatments  include  topical  and  oral  immunosuppressants,  phototherapy,  and  chemical  depigmenting  agents.Emerging  treatments  include  targeted  immunotherapy  and  melanocyte-stimulating  hormones.